These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 26715280)
1. Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma. Sun WY; Jung WH; Koo JS Tumour Biol; 2016 Jun; 37(6):8197-207. PubMed ID: 26715280 [TBL] [Abstract][Full Text] [Related]
2. Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis. Kim HM; Jung WH; Koo JS J Transl Med; 2015 Jul; 13():222. PubMed ID: 26163388 [TBL] [Abstract][Full Text] [Related]
3. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Park SY; Kim HM; Koo JS Breast Cancer Res Treat; 2015 Feb; 149(3):727-41. PubMed ID: 25667103 [TBL] [Abstract][Full Text] [Related]
4. Expression of cancer-associated fibroblast-related proteins in adipose stroma of breast cancer. Jung YY; Lee YK; Koo JS Tumour Biol; 2015 Nov; 36(11):8685-95. PubMed ID: 26044562 [TBL] [Abstract][Full Text] [Related]
5. Expression of CAF-Related Proteins Is Associated with Histologic Grade of Breast Phyllodes Tumor. Kim HM; Lee YK; Koo JS Dis Markers; 2016; 2016():4218989. PubMed ID: 27881889 [No Abstract] [Full Text] [Related]
6. Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma. Park CK; Jung WH; Koo JS Breast Cancer Res Treat; 2016 Aug; 159(1):55-69. PubMed ID: 27469595 [TBL] [Abstract][Full Text] [Related]
7. Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype. Sun WY; Kim HM; Jung WH; Koo JS J Transl Med; 2016 Jun; 14(1):168. PubMed ID: 27277113 [TBL] [Abstract][Full Text] [Related]
8. Differential Expression of Cancer-Associated Fibroblast-Related Proteins in Ductal Carcinoma in situ According to Molecular Subtype and Stromal Histology. Lee JH; Kim HM; Koo JS Pathobiology; 2018; 85(5-6):311-321. PubMed ID: 30223270 [TBL] [Abstract][Full Text] [Related]
9. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights. Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187 [TBL] [Abstract][Full Text] [Related]
10. Expression of Autophagy-Related Proteins in Different Types of Thyroid Cancer. Kim HM; Kim ES; Koo JS Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257096 [TBL] [Abstract][Full Text] [Related]
11. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. Min HS; Lee C; Jung KC J Korean Med Sci; 2013 Apr; 28(4):534-41. PubMed ID: 23580256 [TBL] [Abstract][Full Text] [Related]
12. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas. Gao WL; Wie LL; Chao YG; Wie L; Song TL Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107 [TBL] [Abstract][Full Text] [Related]
13. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956 [TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status. Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767 [TBL] [Abstract][Full Text] [Related]
16. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma. Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810 [TBL] [Abstract][Full Text] [Related]
18. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation. Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496 [TBL] [Abstract][Full Text] [Related]
19. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686 [TBL] [Abstract][Full Text] [Related]
20. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse. Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]